Accolade (ACCD)
(Delayed Data from NSDQ)
$3.56 USD
0.00 (0.00%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $3.55 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.56 USD
0.00 (0.00%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $3.55 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Zacks News
Sprinkler (CXM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sprinkler (CXM) delivered earnings and revenue surprises of 50% and 2.29%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Yext (YEXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Yext (YEXT) delivered earnings and revenue surprises of 40% and 1.22%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar?
by Zacks Equity Research
Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accolade (ACCD) delivered earnings and revenue surprises of -17.39% and 1.82%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Company News for Jan 12, 2022
by Zacks Equity Research
Companies in The News Are: ACCD,PACB,BIG,ILMN
Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accolade (ACCD) delivered earnings and revenue surprises of 18.75% and 9.85%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Accolade (ACCD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 28th
by Zacks Equity Research
ACCD, CMTL, FRO, GP, and KMB have been added to the Zacks Rank #5 (Strong Sell) List on October 28, 2021.
New Strong Sell Stocks for October 19th
by Zacks Equity Research
ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021
Company News for Oct 11, 2021
by Zacks Equity Research
Companies in The News Are: ACCD,CCXI,ALLO,WMT
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accolade (ACCD) delivered earnings and revenue surprises of 4.44% and 4.04%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Accolade (ACCD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
New Strong Sell Stocks for July 12th
by Zacks Equity Research
ACCD, CMTL, HEXO, NTRB, and GP have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2021
New Strong Sell Stocks for July 7th
by Zacks Equity Research
ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.
Will Accolade (ACCD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
Booming Telehealth Market Lures More IPOs and M&A Deals
by Sapna Bagaria
To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.
New Strong Sell Stocks for May 17th
by Zacks Equity Research
ACCD, CEVA, FCEL, GO, and IIPR have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2021
Timing the Market, Is it Possible? - September 28, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
The Truth About Market Timing - August 31, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?